Stephen Harvey
Direttore/Membro del Consiglio presso CastleVax, Inc.
Profilo
Stephen Harvey is currently a Director at CastleVax, Inc. He previously worked as a Senior Vice President-Finance at The Mount Sinai Hospital.
Posizioni attive di Stephen Harvey
| Società | Posizione | Inizio |
|---|---|---|
CastleVax, Inc.
 CastleVax, Inc. BiotechnologyHealth Technology CastleVax, Inc. is an American vaccine platform company based on technology developed at the Icahn School of Medicine at Mount Sinai, headquartered in an undisclosed location. The private company's platform uses a disease virus to induce the human immune system to produce neutralizing antibodies targeted at a range of emerging and pandemic viruses, including SARS-CoV-2. The technology was developed in response to the growing need for vaccine independence and pandemic response preparedness. CastleVax's leading candidate, NDV-HXP-S, is currently being tested in clinical trials in multiple countries around the world. The company was founded by Florian Krammer, Peter Palese, Adolfo García-Sastre. | Direttore/Membro del Consiglio | - |
Precedenti posizioni note di Stephen Harvey
| Società | Posizione | Fine |
|---|---|---|
The Mount Sinai Hospital
 The Mount Sinai Hospital Hospital/Nursing ManagementHealth Services The Mount Sinai Hospital provides medical and healthcare services. The company was founded in 1952 and is headquartered in New York, NY. | Direttore Finanziario/CFO | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 2 |
|---|---|
The Mount Sinai Hospital
The Mount Sinai Hospital Hospital/Nursing ManagementHealth Services The Mount Sinai Hospital provides medical and healthcare services. The company was founded in 1952 and is headquartered in New York, NY. | Health Services |
CastleVax, Inc.
CastleVax, Inc. BiotechnologyHealth Technology CastleVax, Inc. is an American vaccine platform company based on technology developed at the Icahn School of Medicine at Mount Sinai, headquartered in an undisclosed location. The private company's platform uses a disease virus to induce the human immune system to produce neutralizing antibodies targeted at a range of emerging and pandemic viruses, including SARS-CoV-2. The technology was developed in response to the growing need for vaccine independence and pandemic response preparedness. CastleVax's leading candidate, NDV-HXP-S, is currently being tested in clinical trials in multiple countries around the world. The company was founded by Florian Krammer, Peter Palese, Adolfo García-Sastre. | Health Technology |
- Borsa valori
- Insiders
- Stephen Harvey
